Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adverum Biotechnologies Inc

ADVM
Current price
7.66 USD +0.1 USD (+1.32%)
Last closed 7.6 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 157 751 680 USD
Yield for 12 month +583.93 %
1Y
3Y
5Y
10Y
15Y
ADVM
21.11.2021 - 28.11.2021

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Address: 100 Cardinal Way, Redwood City, CA, United States, 94063

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.33 USD

P/E ratio

Dividend Yield

Current Year

+3 600 000 USD

Last Year

+3 600 000 USD

Current Quarter

Last Quarter

-3 600 000 USD

Current Year

-2 044 000 USD

Last Year

-6 528 000 USD

Current Quarter

-997 000 USD

Last Quarter

-4 608 999 USD

Key Figures ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -115 318 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -27.69 %
PEG Ratio
Return On Equity TTM -66.4 %
Wall Street Target Price 35.33 USD
Revenue TTM
Book Value 8.78 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -70 %
Dividend Yield
Gross Profit TTM -81 681 000 USD
Earnings per share -10.2 USD
Diluted Eps TTM -10.2 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ADVM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 21.03.2024
Dividend Date

Stock Valuation ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 61.657
Price Sales TTM 67.6264
Enterprise Value EBITDA -1.8755
Price Book MRQ 2.9167

Financials ADVM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADVM

For 52 weeks

7.24 USD 29.7 USD
50 Day MA 11.43 USD
Shares Short Prior Month 1 199 259
200 Day MA 12.6 USD
Short Ratio 2.31
Shares Short 762 205
Short Percent 3.7 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics